Biotricity, News

Biotricity wins NIH Grant from the National Heart, Blood, and Lung Institute for AI-Enabled real-time monitoring and predictive analytics for stroke due to chronic kidney failure

Biotricity Inc. (Biotricity), today announced that it will be carrying out an NIH-sponsored Phase I study of Bioflux-AI, Biotricity’s innovative artificial intelligence-driven (‘AI’) system of real-time monitoring and prediction technology, in subjects with Chronic Kidney Disease (‘CKD’).  The risk of ischemic and hemorrhagic stroke is 5 to 30 times higher in patients with CKD and has a mortality rate of up to three times that of the general population. Effective stroke risk prediction is currently flawed in CKD patients because comorbidities often remain undiagnosed and stroke risk stratification schemes do not consider stages of CKD. Additionally, the detection of stroke-risk variations due to dialysis requires real-time risk monitoring, which is unavailable to date.


Read More

Biotricity, Financial Results

Biotricity reports financial results for Fiscal 2023 First Quarter

Biotricity Inc. (Biotricity) today announced its financial results for its fiscal 2023 first quarter ended June 30, 2022.  Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, “We are pleased with our year-over-year revenue growth and ability to maintain gross margins at 60% as we begin to roll out our new Biotres and Bioheart products lines through our established network. Both new product offerings will complement the existing platform we have built through Bioflux to make the Biotricity ecosystem an all-in-one go-to solution for cardiologists. Additionally, because Biotres is a higher volume wireless wearable cardiac monitoring device as compared to Bioflux, we expect to expand our distribution to include channels such as Hospital Networks or Integrated Delivery Networks.”


Read More

Biotricity, Financial Results

Biotricity reports financial results for Fiscal 2022 Fourth Quarter and full year

Biotricity Inc. (Biotricity) today announced its financial results for its fiscal 2022 fourth quarter and year ended March 31, 2022.  Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, “Fiscal 2022 was a pivotal year for Biotricity as we made significant strides in our product development and commercialization strategy.


Read More

Biotricity, News

Biotricity to join Russell Microcap(R) Index

Biotricity Inc. (Biotricity) today announced that the company is expected to join the Russell Microcap® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the US market opens on June 27, 2022.  Membership in the Russell Microcap® Index, which remains in place for one year, includes inclusion in the appropriate growth and value style indexes.


Read More

Biotricity, News

Biotricity issues shareholder update

Biotricity Inc. (Biotricity) today provided an update for its shareholders by Chief Executive Officer Waqaas Al-Siddiq, Ph.D., that discusses recent company achievements and strategic initiatives to position the business for strong 2022 results, increasing scale and accelerating growth into 2023.


Read More

Biotricity, News

Biotricity to launch commercial sales of its disruptive cardiac monitoring device, Biotres in April 2022

Biotricity Inc. (Biotricity) will officially launch the commercial sales of its FDA cleared, wireless wearable cardiac monitoring device, Biotres, in April 2022.  The product has been available for pre-orders to physicians, medical offices, hospitals and individual use since late-February 2022.


Read More

Biotricity, News

Biotricity named to Fast Company’s annual list of the World’s 50 Most Innovative Companies for 2022

Biotricity Inc. (Biotricity) has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2022.  Biotricity was also highlighted as #1 in this year’s Medical Devices category.  This year’s list honors businesses that are making the biggest impact on their industries and culture as a whole-ultimately thriving in today’s ever-changing world.


Read More

1 2 3 4 5
Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Youtube
Consent to display content from - Youtube
Vimeo
Consent to display content from - Vimeo
Google Maps
Consent to display content from - Google
Spotify
Consent to display content from - Spotify
Sound Cloud
Consent to display content from - Sound